Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials
Posted: 23 June 2025 | Drug Target Review | No comments yet
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.
This episode, ‘Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials,’ will explore the challenges and successes of moving promising drug candidates from preclinical screening to clinical trials in oncology.
Join Dr. Steve Shnyder, Associate Professor at the Institute of Cancer Therapeutics, University of Bradford, as he explores:
- The unique challenges in oncology drug development.
- Preclinical model limitations and needed innovations.
- Translating preclinical insights into effective clinical trial design.
- The role of AI and machine learning in overcoming development hurdles.
- Real-world case studies of successful oncology drug approvals.
This podcast is brought to you in association with Molecular Devices.
Molecular Devices empowers scientific breakthroughs with innovative life science technology, supporting academic, pharmaceutical, government, and biotech researchers around the world. Visit: moleculardevices.com to learn more.
About Dr. Steve Shnyder
Dr. Steve Shnyder is an Associate Professor in Tumour Biology at the Institute of Cancer Therapeutics, University of Bradford.
Steve earned his PhD from University College London and went on to hold postdoctoral positions at Cardiff University, the University of Bath, and the University of Otago, where he conducted research in osteosarcoma biology, homeobox gene regulation and expression, and the characterisation of a novel reticuloplasmin, respectively. He later worked at Gendel Ltd, a start-up biotechnology company in Coleraine, focusing on novel drug delivery technologies.
Steve joined the Institute of Cancer Therapeutics at the University of Bradford, where he currently coordinates in vitro and in vivo screening of novel anti-cancer therapeutics sourced both in-house and from academic and industry collaborators. His contributions have supported the development of several compounds that have progressed to clinical trials and beyond, including vinflunine (Javlor), combretastatin A-1 diphosphate (Oxi4503), combretastatin A-4 phosphate (fosbretabulin), SJG-136, AQ4N (Banoxantrone), and CYT997 (Lexibulin).
His research focuses on overcoming drug resistance in colorectal cancer. Steve has authored over 75 scientific journal articles and five book chapters on in vivo methodology.
Related topics
Animal Models, Artificial Intelligence, Biomarkers, Cancer research, Clinical Trials, Drug Development, Drug Discovery, Machine learning, Oncology, Translational Science
Related conditions
Cancer
Related organisations
Molecular Devices, University of Bradford
